Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading Down 5.4% – Time to Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s share price was down 5.4% on Friday . The company traded as low as $41.86 and last traded at $42.08. Approximately 514,340 shares traded hands during trading, an increase of 28% from the average daily volume of 400,341 shares. The stock had previously closed at $44.50.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $60.33.

Amphastar Pharmaceuticals Price Performance

The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average of $47.14 and a two-hundred day moving average of $44.63. The firm has a market cap of $2.03 billion, a P/E ratio of 14.08, a PEG ratio of 0.87 and a beta of 0.78.

Insider Buying and Selling

In related news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the transaction, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,533 shares of company stock worth $1,676,542 in the last three months. 27.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMPH. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after purchasing an additional 273 shares in the last quarter. Innealta Capital LLC purchased a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth about $55,000. Point72 Asia Singapore Pte. Ltd. boosted its position in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the period. Blue Trust Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth approximately $78,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.